Cellectis (NASDAQ:CLLS) Research Coverage Started at StockNews.com
StockNews.com assumed coverage on shares of Cellectis (NASDAQ:CLLS – Free Report) in a research note issued to investors on Thursday. The brokerage issued a sell rating on the biotechnology company’s stock. Separately, Barclays reduced their target price on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a […]
More Stories
EU Hosts Emergency Meeting in Response to Trump’s Tariffs Over Greenland
By Jacob Burg The European Union called an emergency meeting of ambassadors from the bloc’s 27 nations on Jan. 18...
Minnesota Gov. Tim Walz Mobilizes National Guard Amid Anti-ICE Protests
By Jacki Thrapp Minnesota Gov. Tim Walz said he has mobilized his state’s National Guard on Jan. 17 and will...
California AG Sends Cease-and-Desist Letter to Musk’s xAI Over Nonconsensual Explicit Images
By Kimberly Hayek California’s top law enforcement official on Friday ordered Elon Musk’s artificial intelligence company xAI to stop the...
IRS Announces $1,776 ‘Warrior Dividend’ for Troops Is Tax-Free
By Jack Phillips The Internal Revenue Service and the Pentagon said on Jan. 16 that a “warrior dividend” announced by...
Landman Season 3: News and Updates on Release Date and Trailer
Landman has gained popularity from its very first season. The season premiered on November 17, 2024, and continued for approximately...
A Dawn of Harmony: Envisioning True Peace Between the United States and Iran
By Stephen Zogopoulos, USNN World News January 17, 2026 – In the shadow of escalating protests across Iran and the...